Key Highlights

  • Loss per share was USD 0.09 against an estimated USD 0.21 loss, and the company reported no revenue.
  • Net loss narrowed to USD 6.2 million from USD 16.4 million, and Research and Development expense was USD 8.5 million.
  • Cash, cash equivalents and restricted cash were USD 26.8 million, and the filing includes a Going Concern note.
  • A USD 6.5 million gain from the change in Fair Value of a Warrant Liability reduced the quarterly net loss.

Biomea Fusion (NASDAQ:BMEA), a clinical-stage biopharmaceutical company focused on metabolic diseases, reported a third quarter 2026 loss of USD 0.09 per share against an estimated loss of USD 0.21. The company reported no revenue, in line with the estimate. Net loss was USD 6.2 million against USD 16.4 million a year earlier, and loss per share was USD 0.27 in the prior-year quarter.

Research and development expense was USD 8.5 million against USD 14.4 million, and general and administrative expense was USD 4.4 million against USD 4.2 million. Operating expenses totaled USD 13.0 million against USD 20.8 million.

Warrant Liability and Nine-Month Results

The quarter included a USD 6.5 million gain from the change in fair value of the common warrant liability, against USD 3.9 million a year earlier. The filing attributes the change to Revaluation of common warrants. Excluding that item and interest income of USD 0.3 million, the loss from operations was USD 13.0 million.

For the nine months, net loss was USD 26.9 million against USD 66.4 million, and loss per share was USD 0.37 against USD 1.45. Research and development expense decreased USD 27.1 million and general and administrative expense decreased USD 4.0 million. The nine-month results include a USD 0.5 million gain on sale of property and equipment.

Cash and Going Concern Note

Cash, cash equivalents and restricted cash were USD 26.8 million at September 30, 2026, and the accumulated Deficit was USD 476.0 million. The filing states these resources, without any future financing, are sufficient to fund operations only into the second quarter of 2027. It also states there is substantial doubt about the company's ability to continue as a going concern and that substantial additional Capital is required.

The company did not issue shares or receive proceeds under its 2022 at-the-market program in the nine months, and USD 94.8 million remained available under it. The filing also states the company does not expect Revenue from product sales unless and until it obtains regulatory approval for and commercializes a product candidate, and that it expects expenses and operating losses to continue for the foreseeable future.

Pipeline and Legal Disclosure

The filing describes icovamenib, formerly BMF-219, as an orally administered investigational small molecule in Phase 2 development for type 1 and type 2 diabetes. It names BMF-650 as a second product candidate, and states the company is substantially dependent on both.

The filing's Legal Proceedings item states the company is not currently a party to any material legal proceedings. The items to follow are financing, cash use, clinical progress and the warrant liability valuation.